These CD44 targeting strategies using HA-based therapeutic NGs can significantly enhance drug (etoposide, salinomycin, curcumin) bioavailability, and treat MDR cancer cells and multicellular spheroids [89]. The gene discussed is CD44; the disease is cancer.